BAX-BAK heterodimer as a pharmacodynamic biomarker of on-target drug action of Mcl-1 inhibitors to evaluate in-vivo effectiveness.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.2582
Abstract: 2582Background: Clinical development of promising small molecule Mcl-1 inhibitors is underway. The Mcl-1 inhibitors act by disrupting complexes of Mcl-1 with pro-apoptotic proteins such as BAK/BIM/... read more here.
Keywords: mcl; pharmacodynamic biomarker; mcl inhibitors; bak heterodimer ... See more keywords